Journal of Addiction Research & Therapy
Open Access

Kashyap S. Marijuana (Cannabis indica).

Afreen RG. Research and Reviews: Journal of Chemistry.

Reed SC, Evans SM (2016) The effects of oral d-amphetamine on impulsivity in smoked and intranasal cocaine users. Drug and alcohol dependence 163: 141-152.

Strickland JC, Bolin BL, Lile JA, Rush CR, Stoops WW (2016) Differential sensitivity to learning from positive and negative outcomes in cocaine users. Drug and Alcohol Dependence 166: 61-68.

Negus SS, Henningfield J (2015) Agonist medications for the treatment of cocaine use disorder. Neuropsychopharmacology 40: 1815.

Cocchi E, Drago A, Serretti A (2016) Hippocampal pruning as a new theory of schizophrenia etiopathogenesis. Molecular neurobiology 53: 2065-2081.

Pickworth WB, Rosenberry ZR, Koszowski B (2016) Toxicant exposure from smoking a little cigar: further support for product regulation. Tobacco control.

Ewald SC, Hurwitz EL, Kizhakkeveettil A (2016) The effect of obesity on treatment outcomes for low back pain. Chiropractic & Manual Therapies 24: 48.

Bell RL, Hauser S, Rodd ZA, Liang T, Sari Y, et al. (2016) Chapter Seven-A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction. International review of neurobiology 126: 179-261.

Bell RL, Hauser SR, Liang T, Sari Y, Maldonado-Devincci A, Rodd ZA (2017) Rat animal models for screening medications to treat alcohol use disorders. Neuropharmacology.

Patel N, Lalwani D, Gollmer S, Injeti E, Sari Y, Nesamony J (2016) Development and evaluation of a calcium alginate based oral ceftriaxone sodium formulation. Progress in Biomaterials 5: 117-133.

Warden A, Erickson E, Robinson G, Harris RA, Mayfield RD (2016) The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies. Pharmacogenomics 17: 2081-2096.

Rao PS, Yallapu MM, Sari Y, Fisher PB, Kumar S (2015) Designing novel nanoformulations targeting glutamate transporter excitatory amino acid transporter 2: Implications in treating drug addiction. Journal of personalized nanomedicine 1: 3.

Rao PS, Saternos H, Goodwani S, Sari Y (2015) Effects of ceftriaxone on GLT1 isoforms, xCT and associated signaling pathways in P rats exposed to ethanol. Psychopharmacology 232: 2333-2342.

Rao PS, Bell RL, Engleman EA, Sari Y (2015) Targeting glutamate uptake to treat alcohol use disorders. Frontiers in neuroscience 9: 144.

Blum K, Downs BW, Dushaj K, Li M, Braverman ER,et al. (2016) THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS. Precision medicine 1: 18.

Hajela R, Abbott P, Newton S. Addiction is Addiction: Understanding the disease in oneself and others for a better quality of life. FriesenPress; 2015.

Ahmed Saadani Hassani MD, Marston BJ, Kaplan JE (2015) HHS Public Access. J Acquir Immune Defic Syndr 68: S257-S269.

Lugoboni F, Levin FR, Pieri MC, Manfredini M, Zamboni L, et al. (2017) Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs. Psychiatry Research 250: 210-216.

Blum K, inventor; Synaptamine, Inc., assignee. Genetic addiction risk analysis for rds severity index. United States patent application US 14/796,989. 2015 Jul 10.